Arius Research, Inc.

U.S. patent issued to Arius Research for anti-CD63 antibody for cancer treatment

Published in Biotech Law Weekly, April 7th, 2006

Arius Research Inc. (ARI) announced that it has received notice from the United States Patent and Trademark Office that U.S. patent No. 7,009,040 was issued for Arius' lead anti-CD63 antibody, AR7BD-33-11A to treat cancer.

Previously Arius announced that it had received a Notice of Allowance in October 2005.

The patent covers the antibody molecule, various uses of the antibody, its derivatives, and a method for using it, and other similar antibodies, to treat cancers such as prostate and breast cancer. Arius has several additional patent applications pending that will continue to enhance the value of this and other important antibody assets.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Law Weekly

Source: Biotech Law Weekly (2006-04-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry